---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009922"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:14:28.965231+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eliem Q1 net loss $13.2M; ETX-810 fails DPNP trial; ETX-155 data inconclusive; LSRP data Q3

## Summary
- Net loss of $13.2M in Q1 2022 vs $18.6M in Q1 2021; cash $149.9M, funded through at least 2023.
- ETX-810 Phase 2a in diabetic peripheral neuropathic pain failed primary endpoint; LSRP trial fully enrolled, topline data Q3 2022.
- ETX-155 Phase 1b photosensitive epilepsy interim results inconclusive due to lower exposure; Phase 2a MDD/PMD enrollment delayed pending root cause.
- Preclinical Kv7.2/3 channel opener on track for IND-enabling studies in 2022; early anxiolytic program for GAD continues.

## SEC filing metadata
- accession: 0000950170-22-009922
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000095017022009922/0000950170-22-009922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000095017022009922/elym-20220516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009922
- JSON: https://secwatch.observer/filing/0000950170-22-009922.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.